ReviewFrontiers in cellular and infection microbiology2021
SARS-COV-2 Variants: Differences and Potential of Immune Evasion.
Review in Frontiers in cellular and infection microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 138 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
138 citing papers in PubMed, 2 syntheses or guidelines pooled it, 234 citations in OpenAlex.
- Technological Barriers to Routine Genomic Surveillance for Vaccine Development Against SARS-CoV-2 in Africa: A Systematic Review.Influenza and other respiratory viruses · 2024Pooled it
- How are countries responding differently to COVID-19: a systematic review of guidelines on isolation measures.Frontiers in public health · 2023Pooled it
- Identification of Four Compounds with S-RBD-Binding and Pseudovirus Entry-Inhibitory Activity.International journal of molecular sciences · 2026Article
- Advances on Sensors and Diagnostics of SARS-CoV-2 Biomarkers.Analytical chemistry · 2026Article
- Impact of the first booster vaccine against SARS-CoV-2 in Chile.Infectious Disease Modelling · 2026Article
- SARS-CoV-2 Variants and Immune Evasion: Mapping the Future of Vaccine Design.Reviews in medical virology · 2026Review
- "You Could Have Prevented It!": attributions of responsibility toward COVID-19 unvaccinated vs. vaccinated individuals.BMC public health · 2026Article
- Article
- Review
- Genomic Surveillance and Molecular Characterization of SARS-CoV-2 Variants During the Peak of the Pandemic in Türkiye.Biochemical genetics · 2025Article
- Metabolomics and Cytokine Signatures in COVID-19: Uncovering Immunometabolism in Pathogenesis.Metabolites · 2025Article
- Tracing the evolutionary pathway of SARS-CoV-2 through RNA sequencing analysis.Scientific reports · 2025Article
- Severe Acute Respiratory Syndrome Coronavirus 2 Variant Infection Dynamics and Pathogenesis in Transgenic K18-hViruses · 2025Article
- [Differential Characteristics of Human Airway Organoids at Different Stages of Differentiation After Respiratory Syncytial Virus Infection].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2025Article
- JN.1 variants circulating in Italy from October 2023 to April 2024: genetic diversity and immune recognition.BMC infectious diseases · 2025Article
- SARS-CoV-2-ORF-3a Mediates Apoptosis Through Mitochondrial Dysfunction Modulated by the KInternational journal of molecular sciences · 2025Article
- RBD-displaying OMV nanovaccine boosts immunity against SARS-CoV-2.Journal of nanobiotechnology · 2025Article
- SARS-CoV-2 Variants: Genetic Insights, Epidemiological Tracking, and Implications for Vaccine Strategies.International journal of molecular sciences · 2025Review
- T and B cell responses in different immunization scenarios for COVID-19: a narrative review.Frontiers in immunology · 2025Review
- Article
78 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The structural spike (S) glycoprotein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) plays an essential role in infection and is an important target for neutralizing antibody recognition. Mutations in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.